Stockwinners Market Radar for March 15, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:28 EDT Orion Engineered CFO buys $238K in common stock - In a regulatory filing, Orion Engineered disclosed that its CFO Jeffrey Glajch bought 10K shares of common stock on March 15th in a total transaction size of $238K.

20:30 EDT Axalta Coating CEO buys $1.0M in common stock - In a regulatory filing, Axalta Coating disclosed that its CEO Chris Villavarayan bought 34.4K shares of common stock on March 13th in a total transaction size of $1.0M.

20:12 EDT Cathie Wood's ARK Investment bought 122.6K shares of Block today

19:37 EDT Celcuity to present preclinical data on Gedatolisib at AACR - Celcuity "announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American Association for Cancer Research, or AACR, which will be held April 14-19, 2023 in Orlando, Florida. The abstract and poster presentation describe the potency and efficacy of gedatolisib and other PI3K/AKT/mTOR inhibitors using cell viability, cell proliferation, and flow cytometry assays in endometrial, ovarian, and cervical cancer cell lines."

19:13 EDT Charles Schwab director buys $2.0M in common stock - In a regulatory filing, Charles Schwab disclosed that its director Stephen Ellis bought 34.4K shares of common stock on March 15th in a total transaction size of $2.0M.

19:04 EDT LGI Homes opens new phase at Hiddeny Valley Farm - LGI Homes announced the opening of a new section at Hidden Valley Farm, an exceptional community located near Fort Collins. This breathtaking neighborhood offers new-construction homes in a peaceful community near an abundance of local parks, shopping and dining establishments, and entertainment options. "We are excited to open a brand-new section at Hidden Valley Farm. Our new-construction homes have everything you're looking for - extra space, all-inclusive upgrades, and excellent curb appeal. From the moment you enter the community, you feel right at home," said Kevin Wolf, Vice President of Operations in Colorado.

18:52 EDT Ryan Specialty Group CEO buys $7.78M in common stock - In a regulatory filing, Ryan Specialty Group disclosed that its CEO Patrick Ryan bought 208.1K shares of common stock on March 14th in a total transaction size of $7.78M.

18:13 EDT Guardant Health co-CEO buys $2.5M in common stock - In a regulatory filing, Guardant Health disclosed that its co-CEO Amirali Talasaz bought 97K shares of common stock on March 13th in a total transaction size of $2.5M.

18:04 EDT ZTO Express sees FY23 parcel volume up 18%-22% y/y - Based on current market conditions and current operations, the company's parcel volume for 2023 is expected to be in the range of 28.78B-29.75B, representing a 18%-22% increase year over year. Relative to the entire industry performance, the company is confident to achieve at least 1.5 percentage point increase in its market share for the entire year.

17:57 EDT Crocs director buys $339.4K in common stock - In a regulatory filing, Crocs disclosed that its director Thomas Smach bought 3K shares of common stock on March 13th in a total transaction size of $339.4K.

17:30 EDT New Mountain Finance chairman Klinsky buys 200,000 common shares - In a regulatory filing, New Mountain Finance chairman Steven Klinsky disclosed the purchase of 200,000 common shares of the company in two transactions. The first 100,000 shares were bought on March 13 at a price of $11.6997 per share, while the second set of 100,000 shares was purchased on March 14 at a price of $11.9577 per share.

17:28 EDT Franco-Nevada sees 2023 total gold eq. sales slightly own to 640K-700K - Expects 2023 GEO sales from Precious Metal assets 490K-530K GEOs, consistent with 2022, but anticipates total GEOs sales 640K-700K, a reduction from 2022 primarily based on lower assumed oil and gas prices. Estimates depletion expense $275M-$305M. Expects to commence funding of the $250M stream on the Tocantinzinho project at the end of Q1.

17:20 EDT iRhythm COO Douglas Devine steps down - On March 10, 2023, iRhythm "announced that, in conjunction with its business transformation, Douglas Devine resigned from his position as Chief Operating Officer of the Company. In connection with his resignation, Mr. Devine and the Company have entered into the Consulting Agreement pursuant to which Mr. Devine will assist with the transition of his role and consult for the Company as an executive advisor following his resignation through July 3, 2024."

17:19 EDT CVR Energy to replace Atlas Air in S&P 600 at open on 3/21 - Apollo Global Management (APO) is acquiring Atlas Air Worldwide Holdings (AAWW) in a transaction expected to close soon pending final conditions.

17:14 EDT Sterling Bancorp enters into plea agreement with DOJ - The Department of Justice said in a statement: "A Southfield, Michigan-headquartered bank holding company has agreed to plead guilty to securities fraud for filing false securities statements relating to its 2017 initial public offering and its 2018 and 2019 annual filings. According to a signed plea agreement that will be publicly filed in court, Sterling Bancorp was the holding company for its wholly owned subsidiary, Sterling Bank and Trust F.S.B. . Sterling - with branches located in San Francisco, Los Angeles, Seattle, New York, and Southfield - completed an IPO in 2017, and the Company's stock began trading on the NASDAQ exchange under the ticker symbol "SBT." "For years, Sterling originated residential mortgages that were rife with fraud to pad its bottom line and then lied about these loans in its IPO and subsequent public filings, defrauding unwitting investors," said Assistant Attorney General Kenneth A. Polite, Jr. of the Justice Department's Criminal Division. "This proposed guilty plea reflects the nature and seriousness of the wrongdoing and demonstrates the Department of Justice's commitment to protecting the integrity of our public markets, holding corporations accountable for their criminal misconduct, and compensating victims for their losses." The largest portion of the Bank's loan portfolio was composed of residential mortgage loans. In or around 2011, the Bank established a residential mortgage loan program known as the Advantage Loan Program or ALP . Between 2011 and 2019, the Bank's employees and agents originated at least $5 billion in ALP loans. The Bank touted the ALP's flexible documentation requirements and fast underwriting and closing capabilities. The program required a minimum 35% down payment and charged higher rates and fees than generally were available elsewhere in the market, but it did not require submission of typical loan documentation, such as an applicant's tax returns or payroll records. "The consequences of this type of financial fraud scheme are damaging and far-reaching," said Assistant Director Luis Quesada of the FBI's Criminal Investigative Division. "The FBI and our law enforcement partners remain committed to protecting good-faith investors and safeguarding the integrity of our markets from companies that commit securities fraud." Reference Link

17:13 EDT Tandem Diabetes announces NEJM publication of study on t:slim X2 insulin pump - The company states: "Tandem Diabetes announced publication of results from the Pediatric Artificial Pancreas Clinical Trial by the New England Journal of Medicine showing an approximate 3-hour per day increase in time in range in children ages 2-5 years old using the t:slim X2 insulin pump with Control-IQ advanced hybrid closed-loop technology compared to those on a standard insulin pump or multiple daily injections. All participants were using a Dexcom G6 Continuous Glucose Monitoring System. Results observed in this randomized, controlled trial for subjects using Control-IQ technology, an automated insulin delivery system, were immediate, sustained, and observed across the spectrum of patient characteristics including race-ethnicity, parental education, family income, baseline glycated hemoglobin level, virtual vs. in-person training format, and pre-study insulin delivery method. Subjects with higher baseline hemoglobin A1c values experienced greater improvements in time in range and A1c during the study."

17:01 EDT Mativ names Greg Weitzel as new CFO - Mativ Holdings "announced that Greg Weitzel will succeed Andrew Wamser as global chief financial officer for the $3B manufacturer of critical components and engineered solutions. Weitzel will assume the leadership of the company's global financial capabilities and services on April 2, 2023 from Wamser, who will depart the company on April 1, 2023."

16:48 EDT Airgain awarded multi-million dollar contract by leading provider of railcars - Airgain "announced that a leading provider of railcars and associated services to the nation's top railways has selected Airgain's NimbeLink asset tracking solution to track and monitor its fleet of railcars. Airgain's cellular-based solution allows organizations to track assets whether indoors, outdoors, or in transit without the need for additional investment in wireless infrastructure. This win is the latest for Airgain in a growing global niche in rail that includes the railways themselves as well as multiple suppliers to the industry, all of whom require simple and reliable connectivity to improve operational efficiency."

16:46 EDT Tyler Technologies chairman sells $2.44M in common stock - In a regulatory filing, Tyler Technologies disclosed that its chairman John Marr sold 7.5K shares of common stock on March 14th in a total transaction size of $2.44M.

16:42 EDT UiPath jumps 14% to $16.69 after Q4 earnings beat and guidance

16:36 EDT Esperion reports disagreement with Daiichi Sankyo over milestone payments - In a regulatory filing, Esperion Therapeutics disclosed: "The company is filing information for the purpose of supplementing and updating certain aspects of the description of its business from that described under the heading, "Item 1. Business" in the company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission on February 21, 2023. As previously disclosed, on March 4, 2023, the company announced the full results from its Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting Regimen - CLEAR - Outcomes trial. CLEAR Outcomes was a global study of nearly 14,000 patients with or at risk for cardiovascular disease who were unable to maximize or tolerate a statin. The study showed that NEXLETOL significantly reduced the risk of hard MACE-4 and MACE-3 by 13% and 15%, respectively, and significantly reduced the risk of heart attack and coronary revascularization by 23% and 19%, respectively, as compared to placebo. These results were seen in a broad population of primary and secondary prevention patients who are unable to maximize or tolerate a statin. The proportions of patients experiencing adverse events and serious adverse events were similar between the active and placebo treatment groups. Bempedoic acid, contained in NEXLEOL and NEXLIZET, now becomes the first LDL-C lowering therapy since statins proven to lower hard ischemic events, not only in those with ASCVD but also in the large number of primary prevention patients for whom limited therapies exist. The company believes that it remains on track to submit regulatory filings to the FDA and EMA in the first half 2023. Based on the robustness of the CLEAR Outcomes data, the company believes it would be entitled to receive $300 million in partner milestone payments upon inclusion of cardiovascular risk reduction data in the EU label, for which payment is tied to the magnitude of the risk percentage reduction included in the label, among other requirements, and ranges from $200 million for the inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate that, based on the CLEAR Outcomes data, is equal or greater than 15% but less than 20% to $300 million if such risk reduction in the EU label that correlates with a relative risk reduction rate is equal or greater than 20%, and up to $140 million in partner milestone payments upon the achievement of other regulatory milestones, including inclusion of certain required cardiovascular risk reduction data in the US label. The company has had communications with Daiichi Sankyo Europe (DSE) regarding potential milestone payments in which DSE has conveyed that it disagrees with the company's assessment that the CLEAR Outcomes data would support the company's right to receive any milestone payments upon inclusion of certain required cardiovascular risk reduction data in the EU label, because the CLEAR Outcomes study showed a 12.98% reduction in MACE-4, the primary endpoint of the trial. The company strongly disagrees and continues to believe that, pursuant to Section 9.2 of the company's license and collaboration agreement with DSE, which refers only to cardiovascular risk reduction and not to any primary endpoint, it would be entitled to receive such payment upon inclusion of cardiovascular risk reduction in the EU label that correlates with a relative risk reduction rate of at least 20%, based on the CLEAR Outcomes trial demonstrating a significant reduction of fatal and non-fatal myocardial infarction by 23%. If necessary, the company intends to enforce its contractual rights and seek the milestone payments it believes it is entitled to. Even if the company is successful in enforcing its rights, there could be a delay in the company's receipt of the milestone payments as a result of any dispute relating to such payments. Any failure to receive or any delay in receipt of the milestone payments may significantly impact the company's future capital needs. In addition, while the company believes it would be entitled to receive such funds upon meeting the foregoing requirements, the company cautions that receipt of any milestone payment amounts is subject to risks and uncertainties, including the company obtaining the relevant regulatory approvals and marketing authorizations, the approval of the required EU and US labels, the absence of any material disagreements or disputes with regulators or our collaboration partners and the ultimate timing and payment of such milestone payment amounts by our collaboration partners. In addition, while the company expects that it will be entitled to the foregoing milestone payments, its inability to receive some or all of its milestone payments and other royalty amounts from its collaboration partners may significantly impact its future capital needs."

16:34 EDT Enovis announces CEO Matt Trerotola named chair of board - Enovis announced that CEO Matt Trerotola will assume the additional position of chair of the board, effective following the company's 2023 annual meeting of stockholders on May 16, when current chair Mitchell Rales, who has informed the board that he will not seek re-election at the annual meeting, will retire. At that time, current Enovis director Sharon Wienbar will become lead independent director. Following the retirement of Rales, the size of the board will be reduced from 11 to 10 directors, and current independent director Angela Lalor will become chair of the compensation and human capital management committee, succeeding current CHCM committee chair Wienbar, who will remain a member of the CHCM Committee.

16:32 EDT Thermo Fisher CEO sells $8.24M in common stock - In a regulatory filing, Thermo Fisher disclosed that its CEO Marc Casper sold 15K shares of common stock on March 13th in a total transaction size of $8.24M.

16:26 EDT Navitas Semiconductor enters SiC distribution pact with Richardson Electronics - Navitas Semiconductor (NVTS) has announced a distribution agreement with Richardson Electronics, (RELL) covering next-generation silicon carbide, or SiC, power semiconductors for the Americas.

16:24 EDT Cian PLC - ADR trading halted, news dissemination

16:20 EDT Tutor Perini announces notice on proposed $2.95B contract for NYC jails facility - Tutor Perini "announced that the City of New York has posted a notice for a public hearing to be held at 10:00 a.m. Eastern Time on March 23, 2023, regarding a proposed contract between the New York City Department of Design and Construction and Tutor Perini Corporation for the Design-Build Program for the NYC Borough Based Jails System, Brooklyn Facility. The proposed contract amount is $2,958,933,292. The contract term is 2,317 consecutive calendar days from the date of notice to proceed."

16:19 EDT L3Harris receives request for more info from FTC over Aerojet deal - L3Harris Technologies (LHX) received a request for additional information from the Federal Trade Commission as part of the regulatory review process for the acquisition of Aerojet Rocketdyne (AJRD). The second request extends the waiting period imposed by the Hart-Scott-Rodino Act until 30 days after L3Harris and Aerojet Rocketdyne have substantially complied with the request, or the waiting period is terminated sooner by the FTC. The transaction is expected to close in 2023, subject to approval by Aerojet Rocketdyne's shareholders tomorrow and other customary closing conditions.

16:18 EDT PG&E names Carolyn Burke as CFO, effective May 4 - PG&E announced that Carolyn Burke will assume the role of Executive Vice President and CFO, effective May 4. She was most recently Executive Vice President and CFO at Chevron Phillips Chemical Company, and previously Executive Vice President, Strategy at Dynegy, where she was part of the executive management team that helped lead the company's emergence from bankruptcy to become a successful power generation and retail electric company.

16:13 EDT CenterPoint Energy appoints Christopher Foster as CFO - CenterPoint Energy appointed Christopher Foster as Executive VP and CFO, effective May 5. Foster joins CenterPoint Energy from PG&E Corporation where most recently, he served as Executive VP and CFO overseeing PG&E's financial activities. Prior to his EVP and CFO role, he held leadership positions in Integrated Grid Planning and Innovation, Investor Relations and Treasury. He began his professional career working as an advisor in the U.S. Congress and held several leadership roles over the course of 10 years.

16:11 EDT Maxeon Solar names Matt Dawson as Chief Technology Officer - Maxeon Solar announced that Matt Dawson will be joining the company on March 20 to serve as Chief Technology Officer. Dawson will be responsible for the research and development function globally, establishing the company's new technology strategic roadmap and leading technological innovation and development. As a senior member of the executive team, Matt Dawson will report directly to the CEO Bill Mulligan. Most recently, Dawson has been Vice President of Technology at Sila Nanotechnologies, a privately held Silicon Valley company working towards scaling up the manufacture of an innovative silicon anode material for advanced high-performance batteries.

16:10 EDT Amtech Systems receives large repeat order for packaging reflow systems - Amtech Systems announced a multi-unit order for high volume reflow systems used in advanced packaging applications. This order, valued at $1.8M, came from a leading OSAT customer of BTU International and will begin shipping this month through the third fiscal quarter of fiscal 2023. With this, the total number of units ordered by this key customer is over 300. The Pyramax reflow oven is the oven of choice for outsourced semiconductor assembly and test due to its combination of extreme control of thermal and atmosphere conditions at very high throughput. "While the semiconductor industry is undergoing a period of uncertainty, we are encouraged by this recent order that serves the advanced computing market," said Michael Whang, CEO of Amtech Systems. "Our relationships with key customers in the OSAT sector are ones we are particularly proud of - and in passing the 300-unit milestone with this customer, it's a credit to the entire team responsible for this account," added Whang.

16:09 EDT InvenTrust Properties raises quarterly dividend to 21.55c per share from 20.5c - This distribution will be paid on or about April 14, 2023, to stockholders of record as of March 31, 2023.

16:05 EDT Robinhood says COO Gretchen Howard to retire at end of 2023 - Robinhood disclosed that Gretchen Howard, its Chief Operating Officer, informed the company of her desire to retire from the company at the end of 2023. Howard will transition to an advisory role on April 3, to support certain special projects for the CEO and will remain employed with the company until January 1, 2024. Howard and the company have entered into a letter agreement to reflect such transition.

15:37 EDT RumbleON largest stockholders to nominate five candidates for board - William Coulter and Mark Tkach, who together own approximately 32.5% of the outstanding Class B shares of common stock of RumbleOn, today an open letter to the company's stockholders. Coulter and Tkach announced that they have nominated five candidates for three board seats that will be up for election to the board of directors of the company at its 2023 annual meeting of stockholders. Coulter and Tkach said in a letter to stockholders: "...We have reluctantly undertaken this process and have tried to avoid it via settlement. Again, we are entrepreneurs, not activist investors. However, we believe that the Board needs several new, well-qualified directors to oversee the type of change required to maximize value for all stockholders. Our nominees include: William Coulter was the co-founder of RideNow and owns 2.62 million RMBL shares (16.2% of total Class B shares outstanding). Mr. Coulter and Mr. Tkach co-founded RideNow in 1989 and expanded the company to include more than 40 stores in eight states. Mark Tkach was the co-founder of RideNow and owns 2.62 million RMBL shares (16.2% of total Class B shares outstanding). Kyle Beaird is the Chief Financial Officer of SCORE Sports, which designs, manufactures and sells youth sports uniforms and equipment. He has led operations and finance in the action sports industry. Mel Flanigan was the Chief Financial Officer of recreational vehicle retailer Camping World Holdings, Inc. and of audio technology firm DTS Inc., both of which were publicly traded. Steve Pully is a founding partner of Speyside Partners, which performs consulting, restructuring and investment banking services for companies and investors. He has been a director on many public company boards. We look forward to engaging with our fellow stockholders and certain members of the Board to move RumbleOn in the right direction. We are enthusiastic about the opportunity to improve RumbleOn's operational performance and start restoring stockholder value. We have little confidence that this will occur at the hand of the existing leadership of RumbleOn."

15:17 EDT Bank of Hawaii reports $10.6B in available borrowing capacity - Bank of Hawai'i Corporation, parent company of Bank of Hawai'i, provided an updated operational overview "in light of recent industry events and continued market volatility." "We have ample liquidity and overall deposit balances remain stable. Our $10.6 billion of open lines and available collateral exceeds the $9.1 billion of uninsured or uncollateralized deposit balances," the company stated in a regulatory filing. Reference Link

13:47 EDT North American rail traffic down 6.1% for the week ending March 11 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending March 11. For this week, total U.S. weekly rail traffic was 458,629 carloads and intermodal units, down 7.6% compared with the same week last year. Total carloads for the week ending March 11 were 229,246 carloads, down 1.5% compared with the same week in 2022, while U.S. weekly intermodal volume was 229,383 containers and trailers, down 13% compared to 2022. North American rail volume for the week ending March 11 ,on 12 reporting U.S., Canadian and Mexican railroads totaled 330,767 carloads, up 1% compared with the same week last year, and 303,627 intermodal units, down 12.7% compared with2022. Total combined weekly rail traffic in North America was 634,394 carloads and intermodal units, down 6.1%. North American rail volume for the first 10 weeks of 2023 was 6,384,871 carloads and intermodal units, down 2.9% compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), Trinity Industries (TRN), Greenbrier (GBX). FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:25 EDT Siemens Energy launches cash capital increase through accelerated bookbuilding - Siemens Energy announced that the executive board of Siemens Energy AG, with the approval of the supervisory board, resolved to launch a capital increase against cash contributions through partial utilization of the authorized capital. "The share capital of Siemens Energy will be increased by up to 10% by issuing new no-par value registered shares against cash contributions under the exclusion of shareholders' subscription rights. The New Shares will carry full dividend rights for the current fiscal year as from 1 October 2022. The offer and sale of New Shares will be exclusively made to institutional investors in a private placement by way of an accelerated bookbuilding process. The private placement will be initiated immediately after this notification. The executive board of Siemens Energy, with the approval of the supervisory board, will determine and announce the final number of shares to be issued, the placement price and the final gross proceeds following the conclusion of the accelerated bookbuilding process. Following the private placement, Siemens Energy will be subject to a lock-up, i.e., an obligation not to, inter alia, issue further shares or financial instruments convertible into shares or to conduct a further capital increase, of 90 days, subject to certain market standard exemptions. Admission of the New Shares for trading in the sub-segment of the regulated market with additional post-admission obligations (Prime Standard) of the Frankfurt Stock Exchange is expected to take place on 21 March 2023. Trading in the New Shares is expected to commence on 23 March 2023. It is intended to include the New Shares in the existing listings of the existing shares of Siemens Energy. The delivery of the New Shares to investors is scheduled for 23 March 2023," the company stated.

12:18 EDT S&P cuts First Republic credit to junk on deposit outflow risk - S&P Global Ratings earlier today lowered its long-term issuer credit rating on First Republic Bank to "BB+" from "A-." The rating agency placed all of its ratings on First Republic on CreditWatch with negative implications. S&P believes the risk of deposit outflows is elevated at First Republic Bank despite the actions of federal banking regulators and the bank actively increasing its borrowing availability to mitigate risk associated with the bank failures over the last week. It expects increased wholesale borrowings to further weigh on First Republic's net interest margin. First Republic's deposit base is more concentrated than most large U.S. regional banks, which presents heightened funding risks in the current environment, S&P said in a statement.

12:10 EDT Microsoft signs 10-year Xbox PC game partnership with Ubitus - Microsoft Gaming (MSFT) chief Phil Spencer said that the Xbox maker and Ubitus, a cloud gaming provider, have signed a 10-year partnership to stream Xbox PC Games as well as Activision Blizzard (ATVI) titles after the acquisition closes. "Our commitment is to give more players, more choice," Spencer tweeted. Reference Link

12:00 EDT Traeger falls -14.9% - Traeger is down -14.9%, or -56c to $3.21.

12:00 EDT FinVolution Group falls -18.3% - FinVolution Group is down -18.3%, or -82c to $3.67.

12:00 EDT JATT Acquisition rises 14.7% - JATT Acquisition is up 14.7%, or $1.43 to $11.17.

11:52 EDT Summit Healthcare Acquisition Corp trading resumes

11:27 EDT Summit Healthcare Acquisition Corp trading halted, volatility trading pause

11:25 EDT Facebook Ireland violated law over data use, Amsterdam court ruled - Meta Platforms' Facebook Ireland violated the law when processing personal data of Dutch Facebook users in the period from April 1, 2010 to January 1, 2020, the court of Amsterdam ruled today. Personal data was used to advertisers and given to third parties without Facebook users being properly informed about this and without a basis in legislation and regulations, the court said. Reference Link

11:11 EDT Lennar says housing shortage should be stabilizing factor for market over time - Says 2023 shaping up to be 'complicated, volatile'. Says no way to anticipate what comes next. Says primary focus is on cash flow. Says projecting flattish number of deliveries in 2023. Says interest rates have continued to be primary headwind. Says housing supply shortage continues to drive customers to stretch their wallet. Says still believes housing market is beginning to find a point of stabilization. Says cancellations have been normalizing lower. Says housing shortages are major concern across the country. Comments taken from Q1 earnings conference call.

10:48 EDT Canadian Pacific, Kansas City Southern announce deal approved by STB - Canadian Pacific (CP) and Kansas City Southern (KSU) the U.S. Surface Transportation Board issued a decision approving the CP and KCS joint merger application, subject to certain conditions, thereby authorizing the two railways to combine to form Canadian Pacific Kansas City, the first single-line railway connecting the U.S., Mexico and Canada. The decision authorizes CP to exercise control of KCS as early as April 14, 2023, at or after which point CP and KCS would combine to create the new CPKC. CP is reviewing the full 212-page decision in detail and in the coming days will announce its plans with respect to the creation of CPKC. CP President and CEO Keith Creel said: "This decision clearly recognizes the many benefits of this historic combination."

10:37 EDT CNH Industrial taking majority stake in Bennamann - CNH Industrial announced it is expanding its alternative fuel capabilities by taking a majority stake in Bennamann, which it calls "a UK-based expert in solutions to capture, repurpose and store fugitive methane emissions for energy use." "By consolidating our share in Bennamann, we are offering our customers a full energy production, storage and distribution service," says Derek Neilson, President Agriculture at CNH Industrial. "This solution can transform farms into mini energy hubs that can satisfy their own energy needs, produce their own natural fertilizer and sell any excess gas on the open market. It also enables them to generate their own electricity. This makes us a true alternative energy enabler, able to serve myriad applications and contribute to a carbon negative future."

10:32 EDT A-Labs reaffirms $20M PIPE investment in HUB at $10 per share - HUB Cyber Security announced that the Israeli investment bank, A-Labs Advisory & Finance Ltd., has reaffirmed its commitment to invest $20M on HUB as an equity PIPE investment at $10 per share, previously made in connection with the company's business combination. This commitment represents a significant premium to current market price. ALabs has already fulfilled more than 10%, or roughly ~$2.2M, of its commitment and expects to complete the remainder of the funding in the near future, HUB said in a statement. Doron Cohen, Managing Director and CEO of ALabs commented that: "We are intimately familiar with HUB and working closely with its management and board of directors over the past 18 months. A-Labs firmly believes in HUB's potential to become one of the influential companies in the cyber arena over the next years and supports it future growth plans with this funding."

10:15 EDT Ambit Biosciences Corp trading resumes

10:04 EDT Billtrust announces LYNXUS as referral partner - Billtrust has announced LYNXUS as a referral partner. The LYNXUS strategic relationship with Billtrust enables its clients to digitize their AR function and get paid faster with an automated solution for credit, invoicing and payments, cash application, as well as Billtrust's Business Payments Network.

10:00 EDT Nine Energy Service falls -10.9% - Nine Energy Service is down -10.9%, or -70c to $5.74.

10:00 EDT Circor rises 10.9% - Circor is up 10.9%, or $2.79 to $28.41.

10:00 EDT Smartsheet rises 17.4% - Smartsheet is up 17.4%, or $6.65 to $44.97.

09:52 EDT Anthony Hsieh urges LoanDepot board to 'cease wasting' stockholder capital - Anthony Hsieh, the Founder and largest voting stockholder of loanDepot, issued a statement in relation to his nomination of Steve Ozonian as a director, saying in part: "The recent challenges in the financial markets highlight the need for responsible stewardship by all corporate boards. Today I call on the Board of loanDepot to avoid the irresponsible expenditure of stockholder capital to wage an unnecessary proxy fight. I have been working together with the Board for nearly four months to bring in a new director who, I am confident, has the skills and perspective needed to work with management to develop a strategy that will help loanDepot emerge from the current economic climate stronger than ever. As the Company has acknowledged in its public filings, I have approximately 57% of combined voting power at loanDepot which I intend to vote in favor of Mr. Ozonian. As it stands, the Board is poised to waste significant financial resources on a potential proxy contest with its largest stockholder over a single, highly qualified independent nominee. Stockholders should ask, 'How did we get here and how much more stockholder capital has to be wasted before we can come to the right conclusion?' The practical and responsible path to save stockholder capital and management's time would be for the Company to nominate Mr. Ozonian, an independent, highly experienced and well-regarded member of the mortgage industry, for election to the Board. I remain passionate about loanDepot's future success and believe bringing Mr. Ozonian's expertise to refresh the Board, while maintaining its current structure, will best position the Company for long-term success. In this challenging economic environment, the Board must make a realistic decision with the best interest of the Company's stockholders, and our Company, in mind."

09:47 EDT Array Technologies reschedules earnings, needs more time to file annual report - Earlier, Array Technologies announced that it filed an amendment to its previously filed Notification of Late Filing on Form 12b-25 with the SEC as it determined it would be unable to file its Annual Report on Form 10-K for the year ended December 31, 2022 within the 15 day extension period, which ends on March 16, as it requires additional time to complete the Annual Report. Based on the extension of the time for filing the Annual Report, the company will now hold the upcoming fourth quarter and full year conference call on March 21, after market close. "The company does not anticipate any material changes to its previously announced unaudited preliminary 2022 numbers nor does the company expect the timing for filing the Annual Report will impact the previously announced 2023 guidance ranges. Additionally, the company does not anticipate the additional five days will affect any of the financial reporting covenants under the credit agreement, dated October 14, 2020, governing the company's term loan facility and revolving credit facility, or under the indenture, dated December 3, 2021, governing the company's 1.00% Convertible Senior Notes due 2028," the company stated in a press release.

09:47 EDT First Republic falls -21.3% - First Republic is down -21.3%, or -$8.43 to $31.20.

09:47 EDT Custom Truck One Source rises 10.8% - Custom Truck One Source is up 10.8%, or 68c to $6.99.

09:46 EDT Silence Therapeutics Plc - American Depository Share trading resumes

09:43 EDT PacWest Bancorp trading resumes

09:43 EDT First Republic trading resumes

09:38 EDT PacWest Bancorp trading halted, volatility trading pause

09:38 EDT Axcelis expects immaterial impact from relationship with Silicon Valley Bank - Axcelis Technologies (ACLS) expects the collapse of Silicon Valley Bank (SIVB) into receivership by the Federal Deposit Insurance Corp. to have an immaterial impact on the Company. The Company has an unused line of credit with the bank and has used the bank for customer receivables, in swept deposit accounts.The Company has banking relationships with multiple U.S. and foreign banks and investment managers and will not have any liquidity issues resulting from the SVB situation. Cash and cash equivalents on December 31, 2022 was $185.6M, of which approximately $39.2M of cash was in foreign jurisdictions. In addition, the Company held $246.6M of short-term investments on December 31, 2022, consisting of U.S. Government and Agency securities.

09:36 EDT Silence Therapeutics Plc - American Depository Share trading halted, volatility trading pause

09:32 EDT Western Alliance trading halted, volatility trading pause

09:32 EDT Nymox granted extension to regain listing requirements - Nymox Pharmaceutical announced that it has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today. Nymox has recently submitted its Market Approval Application for the treatment of benign prostatic hyperplasia, prostate enlargement, in middle aged and elderly men. The MAA was accepted for review by the authorities in Denmark and is currently being reviewed, Nymox siad. Nymox expects to announce further submissions in the near future and will report on news at the appropriate times.

09:27 EDT Argenx announces MHRA approval of VYVGART - argenx announced that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for VYVGART as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody positive. The MHRA approval of VYVGART is based on results from the global Phase 3 ADAPT trial, which were published in the July 2021 issue of The Lancet Neurology. The ADAPT trial met its primary endpoint, demonstrating that significantly more anti-AChR antibody positive gMG patients were responders on the Myasthenia Gravis Activities of Daily Living scale following treatment with efgartigimod compared with placebo. Responders were defined as having at least a two-point reduction on the MG-ADL scale sustained for four or more consecutive weeks during the first treatment cycle. There were also significantly more responders on the Quantitative Myasthenia Gravis scale following treatment with efgartigimod compared with placebo. Responders were defined as having at least a three-point reduction on the QMG scale sustained for four or more consecutive weeks during the first treatment cycle. VYVGART had a demonstrated safety profile in the ADAPT clinical trial. The most commonly reported adverse reactions that occurred more frequently with VYVGART than placebo were upper respiratory tract infections and urinary tract infections.

09:11 EDT Greenpro Capital announces merger of Green-X, CryptoSX - Greenpro Capital announced the merger of its wholly owned Green-X Corp and CryptoSX to develop an STO platform. Green-X is the first Shariah Compliant ESG Digital Asset Exchange licensed by the Malaysia's Labuan Financial Services Authority. CryptoSX is one of earliest digital asset exchange under Cagayan Economic Zone Authority in Philippines to focus on Security Token Offering and has 10 STO listed since 2019. Greenpro is a strategic investor of CryptoSX since 2020 and the merger will leverage the Greenpro vast experience on business incubation, investment advisory and successful track records in Nasdaq listing, Green-X expertise on Islamic finance and ESG investing and CryptoSX knowledge on digital compliance, blockchain, tokenization and digital payments.

09:09 EDT EnWave sells NutraDried Food Company assets to Creation Foods - EnWave announced that it has agreed to sell certain assets of NutraDried Food Company to Creations Foods U.S. Incorporated.. Creations Foods is a portfolio company of Rio Investment Partners. The Asset Sale to Creations Foods includes the Moon Cheese brand, as well as other NutraDried trademarks, auxiliary equipment, and saleable inventory. EnWave has also executed a royalty-bearing commercial license agreement with Creations to produce cheese snacks in the United States. Creations purchased one of the two 100kW Radiant Energy Vacuum machines installed at NutraDried's facility. The REV Purchase Order will generate a margin commensurate with EnWave's target margin for typical REV machine sales. EnWave intends to strategically re-sell the second 100kW REV machine to either a current or new licensed royalty partner in the coming quarters and has already re-sold the 10kW REV machine from NutraDried to a current royalty partner. otal consideration for the License, REV Purchase Order, and Asset Sale was $2M, plus the cost of select saleable inventory, which will be paid over two years. The majority of the proceeds will be received within 270 days and are expected to more than cover the total cost of the orderly wind-down and dissolution of NutraDried. Creations Foods will seamlessly takeover the production, sale, and distribution of the Moon Cheese product portfolio. All NutraDried customers have been informed of this transition and both parties are optimistic about the future for the better-for-you snack brand. Creations Foods will also entertain bulk dried cheese opportunities that complement their branded product business. Pursuant to this operating transition, NutraDried has assigned its lease to Creations Foods beginning April 1, 2023.

09:07 EDT Golar LNG closes acquisition of New Fortress Energy stake in FLNG Hilli - Further to the announcement on February 6, 2023, Golar LNG Limited confirms today that the agreement to acquire New Fortress Energy Inc.'s interest in FLNG Hilli, effective January 1, 2023, has closed. In return for NFE's 50% Common Unit holding in Golar Hilli LLC, Golar has transferred its remaining 4.1 million NFE shares to NFE, paid NFE $100 million in cash, and assumed approximately $323 million of FLNG Hilli debt.

09:06 EDT STB approves Canadian Pacific to acquire Kansas City Southern with conditions - Reference Link

09:04 EDT LPL Financial: Zion Capital joins broker-dealer, RIA, custodial platforms - LPL Financial announced that financial advisors Lucas Mijares and Jesse Ettlin have launched an independent practice, Zion Capital Wealth Management, and joined LPL Financial's broker-dealer, RIA and custodial platforms. They have aligned with Mariner Advisor Network, an existing firm supporting LPL-affiliated advisors. The advisors of Zion Capital Wealth Management reported having served $185 million in advisory, brokerage and retirement plan assets. They join from Edward Jones. Based in Grass Valley, Calif., Zion Capital Wealth Management is led by managing partners and co-founders Mijares and Ettlin. Friends and colleagues since 2016, the advisors said their shared values and convictions led them to establish Zion Capital. They are joined by Ariel McCormack, Brittney Still and Veronica Broskey, who will serve as office support and client services associates. Together, they believe all clients, regardless of their level of wealth or season of life, deserve an integrated team focused on bettering their financial futures.

09:03 EDT GSE Systems selected by Olkiluoto Nuclear Power Plant - GSE Solutions announced that they were selected to upgrade the OL1 and OL2 training simulators at Olkiluoto Nuclear Power Plant, located in Eurajoki, Finland. The Olkiluoto Nuclear Power Plant is owned by Finnish nuclear power company Teollisuuden Voima Oyj [TVO]. It is widely recognized for its record of safe operations, high availability, and decades of environmentally friendly electricity generation. GSE built the original OL1 and OL2 simulators in the 1980's. Since then, GSE has continued to service and upgrade the simulators at various delivery points. This contract will be fulfilled in two stages between now and August 2025 and will include the following: An upgrade to the plant containment building model with a new JTopmeretTM based model for the OL1 and OL2 training simulators; A replacement of the existing Theatre-based reactor thermohydraulic model with GSE's latest RELAP 5-HD solution; These upgrades will enhance the operator's experience, taking advantage of the latest advances in simulation technology to provide even more realism to the training sessions and see phenomena not previously available with the legacy systems.

09:02 EDT Broadcom shipping Tomahawk 5 family of Ethernet chips in production volume - Broadcom announced that the Tomahawk 5 family of Ethernet switch/router chips is now shipping in production volume. Unprecedented for a chip of its scale, Tomahawk 5 is now available for production deployments, in only seven months from initial samples.

09:00 EDT Inhibikase Therapeutics provides interim update from study of IkT-001Pro - Inhibikase Therapeutics provided an interim update from the dose escalation portion of its '501' bioequivalence study of IkT-001Pro, the Company's prodrug formulation of imatinib mesylate designed to enhance the safety and efficacy of imatinib in patients with Chronic Myelogenous Leukemia, or CML. The 501 trial is evaluating IkT-001Pro at four single ascending doses in the dose escalation portion of the study to select the bioequivalent dose, followed by a dose confirmation portion to confirm the bioequivalent dose. The study will enroll a total of 59 male and female healthy volunteers, aged 25 to 55. The study is designed to evaluate the safety profile of IkT-001Pro as well as compare the pharmacokinetic exposure of IkT-001Pro to the standard of care dose of 400 mg imatinib mesylate in order to identify a bioequivalent dose. As of March 15 the Company has enrolled 19 of 27 healthy volunteers in the dose calibration portion of the study, completing 3 of 4 planned escalating doses at 300, 400 and 500 mg IkT-001Pro. To date, IkT-001Pro has shown a favorable safety profile, with only 4 mild adverse events observed, none of clinical significance. IkT-001Pro has high oral bioavailability and a pharmacokinetic profile of delivered imatinib that closely matches the exposure of imatinib delivered as 400 mg imatinib mesylate. Upon completion of the dose escalation phase, the Company will conduct a confirmatory analysis of the bioequivalent dose of IkT-001Pro in 32 additional healthy volunteers using a two-period crossover design. The Company remains on track to complete the 501 trial in the Q2. Following the completion of the 501 trial, Inhibikase plans to initiate a discussion with the FDA on the parameters for approval of IkT-001pro under the 505 statute.

08:57 EDT Blink Charging unveils redesigned mobile EV charger - Blink Charging announced the immediate availability of its redesigned Blink mobile charger. The freestanding charger is built to provide emergency charging for stranded electric vehicles, directly addressing the needs of EV fleet operators, roadside assistance providers, insurance companies, auto manufacturers, and public roadway assistance programs. The Blink mobile charger is rated at 32 amps and charges an EV with up to 0.5 to 1 mile of range per minute, allowing a stranded vehicle to receive adequate charge to drive to the nearest EV charging station and eliminates the need for the vehicle to be towed. The mobile charger is capable of Wi-Fi connectivity allowing roadside providers to charge EV drivers a flat fee or per usage during a roadside event. The unit is compatible with all electric vehicles and Level 2 fleet vehicles, including all Tesla models.

08:51 EDT Altamira Therapeutics announces presentation of animal data with SemaPhore - Altamira Therapeutics announced the upcoming presentation of animal data generated by a leading US-based osteoarthritis research group. The data show effective attenuation of osteoarthritis progression through treatment with an mRNA therapeutic, delivered in nanoparticles based on the Company's SemaPhore delivery platform. The data will be presented in a late-breaking poster at the 2023 Osteoarthritis Research Society International World Congress in Denver CO. The research group from the Washington University School of Medicine, and University of South Florida tested the delivery of DNA-methyltransferase 3 beta mRNA with Altamira's peptide-based SemaPhore nanoparticles to boost DNMT3B expression in a mouse model of meniscal injury. DNMT3B is a protein coding gene which provides instructions for the making of the DNMT3B enzyme which plays a key role in the homeostasis and metabolism of chondrocytes. Previous studies have suggested that a deficiency in DNMT3B accelerates joint degeneration and may trigger osteoarthritis. The research group treated mice with meniscal injury by local administration of DNMT3B mRNA nanoparticles or controls once every 2 weeks for 12 weeks. Active treatment resulted in strong induction of DNMT3B protein as well as significantly reduced bone sclerosis, cartilage degeneration, and synovitis. Functional studies showed significantly decreased pain sensitivity and improved weight bearing in active treated mice compared to controls.

08:44 EDT Kanen Wealth Management urges CarParts.com to form strategic review committee - David Kanen, president of Kanen Wealth Management, wrote in part, "I am writing on behalf of Kanen Wealth Management, LLC which, together with its affiliates, is one of CarParts.com's largest stockholders, owning approximately 3 million shares of the Company's common stock. As you know, we have attempted, on multiple occasions, to privately address our concerns with management's failure to meaningfully generate stockholder value at PRTS. These engagements have been to no avail. Unfortunately, we are now forced to publicly communicate our frustrations in a way that may be unflattering to Mr. Meniane and the Company's Board of Directors/ As you may be aware, in early 2019, when Mr. Mehran Nia and I had recently joined the Board, the Company's market cap was approximately $40 million. By April of 2021, just two years later, PRTS's stock was approximately $17 per share and the Company's market cap had risen to over $815 million. At that time, Mr. Nia and I had both resigned from the Board to pursue other ventures, thinking that the Company was well-positioned for continued growth. Sadly, we were mistaken, as since then, the Company's market cap has declined by half a billion dollars and PRTS's stock price now sits at less than $6 per share...Therefore, we strongly recommend that the Company immediately take the following actions to restore stockholder value at PRTS: 1) Repurchase shares under the previously announced $30 million share repurchase program announced in 2022; 2) Conduct a detailed and thoughtful expense rationalization program; 3) Halt any further equity dilution until stockholder value is restored to peak levels; 4) Form a strategic review committee to explore alternatives that maximize stockholder value including a sale of the Company; 5) Re-instate me as a shareholder representative in the boardroom; and 6) Consult with Mr. Nia to determine his desire and willingness to be re-instated as a director to the Board, and appoint him to the Board if he's so willing to serve. We hope that this serves as a wake-up call to management and the Board and begins a productive and collaborative dialogue. Otherwise, we intend to take all steps necessary to restore stockholder value at PRTS."

08:41 EDT Atlis Motor Vehicles releases battery cell data for its pouch cell - Atlis Motor Vehicles unveiled battery cell data for its proprietary pouch cell. Atlis' NMC pouch cells successfully meet the targets necessary to enable 15-min charging and ensure consistent performance. Internal testing shows cells with up to 254 Wh/kg energy density, 1.74 mAh average internal resistance, and the ability to maintain 80% usable capacity after 2,000 cycles. "We're on track to meet one of our first goals - to develop a battery cell capable of high performance," said Mark Hanchett, Founder and CEO of Atlis Motor Vehicles. "Our next step is to put these in a battery pack for delivery to our first set of customers. As an execution focused company, generating revenue in 2023 is a critical goal for the company and we're proud to be hitting projected targets along the way." Successful development of Atlis battery cells should inspire confidence in the Company's ability to deliver battery packs to customers in the near future. Atlis intends to ship its first battery packs during the first half of 2023.

08:40 EDT Reborn Coffee launches line of Super-Premium cold brew ice creams - Reborn Coffee announced the launch of a new line of Super-Premium Reborn Cold Brew Ice Creams to be marketed and distributed throughout the Company's retail locations. "Super-Premium cold brew ice cream is a natural extension of our brand, mission and innovative specialty roasted coffee, and we are incredibly excited to begin offering these initial flavors to customers," said Jay Kim, Chief Executive Officer of Reborn. "Our customers, including young urban professionals with high disposal incomes and brand conscious college students, are ideal demographics to target with luxurious and Super-Premium ice creams with flavors that appeal to their coffee-loving palettes. Our first few production test runs have focused on fine tuning and perfecting the product and procedures on an industrial scale in preparation for a major roll out to buyers and consumers in the coming months."

08:38 EDT Acer Therapeutics announces presentation at upcoming meeting for SIMD - Acer Therapeutics announces data will be presented from a survey designed to quantify preferences of healthcare providers for Urea Cycle Disorders, UCDs, at the upcoming 44th Annual Meeting of the Society for Inherited Metabolic Disorders, SIMD, March 18th-21st in Salt Lake City, Utah. Results from the discrete choice experiment will be available on Acer's website following the poster presentation at SIMD on March 19 by Dr. Robert Steiner. "Quantifying Preferences for Urea Cycle Disorder Treatments Using a Discrete-Choice Experiment." This poster summarizes results from a web-based, quantitative survey study using a discrete choice experiment methodology. This study sought to capture the perspectives of healthcare providers with experience treating UCDs to quantify the attributes of nitrogen-binding medications for UCDs that may influence overall prescription and patient adherence. ACER-001 Palatability Data Presented at SIMD and GMDI 2022: Taste-Masked Coating of Sodium Phenylbutyrate Improves the Palatability of Sodium Phenylbutyrate for Treatment of Urea Cycle Disorder. Results from two Phase 1, open-label, repeated measures, taste assessment studies of ACER-001 suspension and sodium phenylbutyrate powder were presented at the SIMD Annual Meeting and Genetic Metabolic Dieticians International Conference in April 2022 and May 2022, respectively. ACER-001 for the treatment of UCDs is now marketed in the U.S. as OLPRUVA following FDA approval in December 2022. OLPRUVA Program Update: Acer also provided an update on its commercial launch activities for OLPRUVA in advance of the SIMD Annual Meeting. To support the launch of OLPRUVA(TM) in Q2 2023, the company is actively adding resources to establish its commercial and medical affairs presence in the U.S. As a part of its OLPRUVA commercialization strategy, Acer has recently introduced its patient support service, OLPRUVA Navigator by Acer Therapeutics, that is designed to assist UCD patients with support, access, education, and patient adherence to treatment. Representatives will begin accepting prescriptions in late Q2 2023. Acer is also actively engaged in negotiations regarding access for OLPRUVA(TM) with the major commercial payers and state Medicaid organizations.

08:37 EDT BTCS releases Android application for StakeSeeker - BTCS announced the release of its Android application for its non-custodial staking platform, StakeSeeker. The app is currently available for download in the Google Play Store.

08:37 EDT Roblox reports February revenue $214M-$217M - Roblox released certain key metrics for the month of February. Daily active users, or DAUs, were 67.3M, up 22% year-over-year. Hours engaged were 4.6B, up 24% year-over-year. Estimated revenue was between $214M and $217M, up 20%-22% year-over-year. Estimated bookings were between $243M and $247M, up 18%-19% year-over-year. Estimated average bookings per daily active user were between $3.61 and $3.67, a decline of between 2%-4% year-over-year.

08:35 EDT ZimVie announces additional policy decisions for VBT - ZimVie announced that Highmark, one of America's leading health insurance organizations and an independent licensee of the Blue Cross Blue Shield Association, which covers primarily Pennsylvania, New York, Delaware, and West Virginia, and BCBS North Dakota, the largest payer in the state of North Dakota, have issued positive medical policy decisions applicable to vertebral body tethering, VBT. Effective January 30, 2023 for Highmark and March 6, 2023 for BCBS North Dakota, the policies outline the criteria for medical necessity and expand potential treatment eligibility to patients indicated for VBT within the 4+ million members covered under Highmark and the 280,000+ lives covered by BCBS North Dakota. "The Highmark and BCBS North Dakota coverage decisions validate the expectation we noted when we announced the Anthem BCBS positive coverage decision in July, that additional policy updates would follow. It is encouraging to see broader endorsement of this opportunity to positively impact the lives of children with scoliosis through a motion preserving alternative to spinal fusion," said Rebecca Whitney, SVP and President of Global Spine for ZimVie. "We are honored to work with orthopedic and neurosurgeons to develop vertebral body tethering solutions that may allow children with scoliosis to return to their active daily lives."

08:32 EDT ThermoGenesis rolls out new facility in the Sacramento metro area - ThermoGenesis announced that the company is rolling out a new facility in the Sacramento metro area, containing a total of 12, class-7, ReadyStart cGMP Suites available for lease by early-stage life science and cell gene therapy companies. The roll-out of the ReadyStart Suites is part of ThermoGenesis' previously announced plan to transform from a medical device company to a contract development and manufacturing organization in the cell gene therapy field. The facility is expected to be available for customers in the second or third quarter of this year. If fully occupied, the facility is anticipated to generate an estimated $10M-16M in annual revenue.

08:22 EDT Edesa Biotech, FDA agree on primary endpoint for Phase 3 ARDS drug study - Edesa Biotech reported that the company and the U.S. Food and Drug Administration have agreed on the primary endpoint and population for a pivotal Phase 3 study evaluating Edesa's monoclonal antibody candidate, EB05, as a therapy for hospitalized patients with a severe form of respiratory failure. The FDA recently granted the program Fast Track designation. Edesa believes that its investigational drug regulates the overactive and dysfunctional immune response associated with Acute Respiratory Distress Syndrome, a severe respiratory illness that can result in long ICU stays and high mortality rates. The agreement announced today follows favorable Phase 2 results, which demonstrated compelling evidence of EB05's ability to reduce mortality in the sickest patients. Among the results, critically ill hospitalized Covid-19 patients given EB05 plus standard of care treatment had an 84% reduction in the risk of dying when compared to placebo plus standard of care at 28 days. Under the amended protocol design, Edesa will evaluate a single cohort of severely ill patients on invasive mechanical ventilation, both with and without additional organ support such as extracorporeal membrane oxygenation. Edesa plans to enroll approximately 600 evaluable hospitalized subjects. The primary endpoint will be the mortality rate at 28 days. The number of ventilator free days at 28 days and mortality at 60 days will also be measured as key secondary endpoints. Dr. Nijhawan said that the amended U.S. protocol has been approved by the study's independent ethics committee. The company reported that recruitment at U.S. hospital sites has been initiated and will scale up in the upcoming quarters as investigational sites complete training on the amended protocol.

08:15 EDT Onconova announces upcoming poster presentations at the AACR annual meeting - Onconova Therapeutics announced the publication of two abstracts that have been accepted for poster presentations at the American Association for Cancer Research, AACR, Annual Meeting, which is taking place at the Orange County Convention Center in Orlando, Florida from April 14 - 19, 2023. Poster Title: Synergistic activity of the CDK4/6 antagonist narazaciclib with irreversible BTK inhibition in ibrutinib-resistant mantle cell lymphoma. This poster will describe studies evaluating narazaciclib in preclinical models of mantle cell lymphoma. Results from these studies demonstrated narazaciclib's single-agent antitumor activity in MCL cell lines independent of their sensitivity to ibrutinib, which is a Bruton's tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration for the treatment of MCL. When combining narazaciclib with ibrutinib, synergistic increases in antitumor activity against both BTKi-resistant and BTKi-sensitive MCL cell lines were observed. Poster Title: Differential targets engaged by narazaciclib in comparison to the approved CDK4/6 inhibitors contribute to enhanced inhibition of tumor cell growth. This poster will describe cell-based, in vitro, and bioinformatic analyses comparing narazaciclib and palbociclib. Results from a cell-based murine mammary carcinoma model showed a stronger induction of programmed cell death with narazaciclib compared to palbociclib. The results of additional cell-based assays that will be described in the poster suggest that narazaciclib may promote antitumor immunity and show that combining narazaciclib with autophagy inhibitors sensitizes breast cancer cells to cell death.

08:13 EDT Spring Lane increases Project Dorothy stake in exchange for $7.5M - Soluna Holdings, the parent company of Soluna Computing, a developer of green data centers for Bitcoin mining and other intensive computing, announced that it completed the final tranche of a series of project-level agreements for $7.5M of fresh capital to fund the Dorothy project and corporate expenses from funds managed by Spring Lane Capital. On February 10, $1.2M of the capital was funded and used for operations and construction. The remaining capital will be used to help complete the substation interconnection and the final stages of Project Dorothy, Soluna's flagship project in West Texas, and corporate operations of Soluna. SLC has been a strategic partner for Soluna at the project and corporate levels of the business since 2022. In this series of transactions, SLC has increased its stake in Project Dorothy 1A from approximately 32% to 85%. Soluna continues to own 100% of Dorothy 1B. After SLC realizes an 18% IRR hurdle on its investments, Soluna retains the right to 50% of the profits on Dorothy 1A. This additional investment implies a total approximate estimated value of $30 million for Project Dorothy. John Belizaire, CEO of Soluna Computing, stated, "Unlocking the mechanisms to make renewable energy a superpower is a shared goal by Soluna and Spring Lane Capital, which makes us strong partners. Through our relationship, we have seen the robust capabilities of the SLC team, and they have seen the strong team we have to execute in a challenging environment. We are excited to continue our partnership as we bring Project Dorothy to energization, and use this as a blueprint for future projects."

08:11 EDT Alpha Teknova, Sartorius BIA Separations announce collaboration - Alpha Teknova and Sartorius BIA Separations, which is part of the international life science group Sartorius, announced that the companies have entered into a collaboration arrangement that will help gene therapy companies streamline the downstream purification process. The collaboration highlights two essential components necessary for the successful recovery of empty and full AAV capsids during anion-exchange purification: the separation technology and the buffer composition. With Sartorius BIA Separations' proprietary AAV platform designed to optimize the separation of viral particles, and Teknova's custom, high-quality buffer solutions developed to maximize capsid enrichment, the companies conducted a robust design of experiment and successfully created a screening kit with optimized buffer formulations that drive consistency and increased purity when paired with the BIA CIMmultus QA monolith. "We're thrilled to find a like-minded partner with Sartorius BIA Separations, a well-respected, global leader in monolith-based technologies who shares our vision of making solutions possible," said Stephen Gunstream, Teknova's President and Chief Executive Officer. "Through our collaboration, we're finding new tools to help our customers streamline the development of AAV therapies by optimizing their purification process and increasing the yield and purity of their AAV product."

08:09 EDT Innovation Pharmaceuticals announces new antifungal testing of Brilacidin - Innovation Pharmaceuticals announced that based on positive findings new testing of Brilacidin in additional in vitro and in vivo models against hard-to-treat fungal pathogens is planned by NIH/NIAID-affiliated and other academic researchers. Brilacidin is the Company's defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties. Extensive in vitro testing of Brilacidin by these research groups against multiple pathogenic human fungi has been completed. Comparable to findings observed in testing by scientists at the University of Sao Paulo, Brazil, Brilacidin showed potent stand-alone inhibition in multiple isolates of C. neoformans, for which few effective treatments exist. Brilacidin showed promising stand-alone inhibition as well in multiple isolates of Mucorales, Fusarium sp., C. glabrata, C. parapsilosis, C. guillermondii, Lomentospora prolificans, Scedosporium apiospermum, Blastomyces dermatitidis and Histoplasma capsulatum. USP researchers have also shown Brilacidin to be synergistic with caspofungin in different types of fungi. Additive effects were similarly observed in Brilacidin combinations with voriconazole and geldanamycin against A. fumigatus, as well as with posaconazole against Mucorales. Separate in vitro laboratory testing evaluating Brilacidin in combination with other conventional antifungals - including caspofungin, fluconazole, posaconazole, amphotericin B and micafungin - demonstrated additive or synergistic inhibition of fungal growth. In related news, Brilacidin antifungal data was accepted for a scientific poster presentation at the 16th Annual European Conference on Fungal Genetics, held in Innsbruck, Austria, March 5-8, 2023, based on research conducted at USP and other academic institutions.

08:07 EDT Nemaura includes insulin on list of drugs eligible for EU DuoPack license - Nemaura Medical announced that it now includes insulin on the list of drugs under the DuoPack Commercial License Agreement with its licensee, MySugarWatch DuoPack Limited, MSWDL. The two companies have now agreed to include injectable insulin for the European market as part of this agreement, as patent expiry allows, in addition to the originally agreed upon medicines. It is estimated that as many as 4 million older patients of the approximately 20 million patients in the combined territories of UK and the EU with Type 2 diabetes receive insulin. "The inclusion of insulin in our agreement with MSWDL means patients with Type 2 diabetes will have access to a CGM-guided insulin dose titration care model that is designed to reduce hypoglycemic episodes and hospital admissions while improving long-term outcomes," commented Nemaura CEO Dr. Faz Chowdhury. "Moreover, it uniquely avoids a potentially bruised, slow to heal, infection prone, needle induced skin puncture wound in older patients at the site of a CGM sensor skin application. We are eager to provide potential improvements in monitoring and lifestyle for the millions of Type 2 diabetes patients globally."

08:05 EDT Global Crossing Airlines granted amended Foreign Air Operators Certificate - Global Crossing Airlines Group has amended its Foreign Air Operators Certificate issued by Transport Canada. The Amended Canadian FAOC adds the number of, and type of, aircraft GlobalX can provide as part of its charter and ACMI offering into Canada from the US, including operating on behalf of existing Canadian airlines.

08:05 EDT Bionano Genomics expands clinical testing menu with launch of two LDTs - Bionano Laboratories announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests, LDTs, based on optical genome mapping, OGM, OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants, SVs, and provide comprehensive testing for most common and rare chromosomal abnormalities. "We are pleased to see the launch of Bionano Laboratories' LDTs for postnatal and prenatal analysis, which can assist patients in their diagnostic and prognostic journey. These LDTs are designed to provide a comprehensive evaluation of genome wide SVs that we believe will assist clinicians in assessing the best potential medical management for their patients," stated Justin Leighton, vice president of laboratory business at Bionano Laboratories.

08:04 EDT Trinity Capital increases dividend 2.2% to 47c - Trinity Capital announced that on March 14, its Board of Directors declared a cash dividend of 47c per share with respect to the quarter ending March 31. This dividend represents an increase of 2.2% over the regular dividend declared in the prior quarter.

08:03 EDT Prelude Therapeutics, BeiGene enter clinical trial collaboration - Prelude Therapeutics (PRLD) announced a clinical trial collaboration with BeiGene (BGNE), for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination with BeiGene's BTK inhibitor, zanubrutinib, in hematologic malignancies.Inhibition of BTK is an active therapeutic approach in several B cell malignancies and the combination of CDK9 inhibition with BTK inhibition has demonstrated, in recent data publications, synergistic clinical efficacy over BTK inhibition alone; hence, there is a strong rationale for studying the combination in patients with certain hematologic malignancies. Under terms of the clinical trial collaboration agreement, BeiGene will provide zanubrutinib to Prelude, and Prelude will retain all global operational, development and commercialization rights and responsibilities for PRT2527.

08:02 EDT Statera BioPharma enters LOI for merger with Worksite Labs - Statera Biopharma has entered into a non-binding letter of intent with Worksite Labs, setting out the initial proposed terms and conditions pursuant to which the Company and Worksite Labs intend to affect a business combination by a merger structure to be determined involving the Company, one or more merger entities of the Company and WSL. The entities resulting from the Proposed Transaction are expected to continue to carry on the business of WSL as a premier, full-service diagnostic testing company that generated 2022 revenues of over $50M. The Company intends to issue a subsequent news release with additional details regarding the Proposed Transaction, including the proposed capitalization of the Company on a post-merger basis, upon execution of the definitive agreements. Completion of the Proposed Transaction is subject to, among other matters, the completion of due diligence, the negotiation of definitive agreements providing for the Proposed Transaction, and satisfaction of a number of conditions negotiated therein, including, but not limited to regulatory approvals including FINRA, and board of directors' and shareholder approvals. There can be no assurance that the parties will successfully negotiate and enter into definitive agreements regarding the Proposed Transaction, or that the Proposed Transaction will be completed as currently contemplated, or at all.

07:51 EDT Roivant Sciences reports results from ADORING 2 Phase 3 trial of VTAMA - Dermavant Sciences announced results from ADORING 2, one of two double-blind, randomized, vehicle-controlled Phase 3 studies to evaluate the efficacy and safety of topical VTAMA cream, 1% in pediatric subjects down to 2 years old and adult subjects with atopic dermatitis. In ADORING 2, VTAMA cream met the primary endpoint of the trial and demonstrated highly statistically significant improvement in the vIGA-AD score of clear or almost clear with at least a 2-grade improvement from baseline at Week 8. Additionally, VTAMA cream demonstrated highly statistically significant improvement in the proportion of subjects with greater than75% improvement in EASI75 from baseline at week 8, a key secondary endpoint. Subjects 12 years and older receiving VTAMA cream also experienced a highly statistically significant improvement greater than4-point reduction in Peak Pruritis Numeric Rating Scale in itch, another key secondary endpoint in the study due to its prevalence among AD sufferers. Both adult and pediatric AD subjects receiving VTAMA cream, 1% did so at the same dose and dose regimen as already approved for adults with plaque psoriasis. Subject to FDA approval in AD, the company believes this could be a key manufacturing, supply chain, and commercial advantage, offering simplicity of treatment to both physicians, pharmacists, and patients, regardless of diagnosis. In ADORING 2, pediatric and adult subjects with atopic dermatitis were randomized at a 2:1 ratio to receive once daily treatment with VTAMA cream, 1% or vehicle cream. At week 8, 46.4% of subjects treated with VTAMA cream in ADORING 2 achieved the primary endpoint of a vIGA-AD of clear or almost clear with at least a 2-grade improvement from baseline at Week 8. Also at week 8, 59.1% of subjects treated with VTAMA cream in ADORING 2 achieved the key secondary endpoint of the proportion of subjects with greater than75% improvement in EASI. 52.8% of subjects greater than or equal to12 years old, with a baseline PP-NRS score greater than or equal to4, achieved a greater than or equal to4-point reduction in the PP-NRS at Week 8. Importantly, VTAMA cream data indicated no safety or tolerability signals in this population including children as young as 2 years old. Adverse events were mild to moderate with a low study discontinuation rate due to adverse events. Adverse events of special interest included contact dermatitis and follicular event.

07:46 EDT Jacobs to manage infrastructure program for Fulton County schools in Atlanta - Jacobs was selected by Fulton County Schools in Atlanta, Georgia to manage the Education Special Purpose Local Option Sales Tax Capital Improvement Program. The current program will implement FCS' Capital Plan 2027, which includes $648M in capital improvements for FCS facilities, safety and technology systems. Under the new 66-month contract, Jacobs will manage infrastructure modernization projects, including the new construction of five schools, and major renovations of 18 other schools and two non-instructional facilities within the school district.

07:43 EDT Polaris Renewable Energy announces $10M term loan facility - Polaris Renewable Energy has signed an agreement with Export Development Canada for a $10M USD Floating Rate Term Loan Facility. The purpose of the Facility is to provide capital to fund early-stage development expenses required to take projects to the point of being construction ready. The Facility has been closed on an undrawn basis. Any drawdowns on the Facility in the future are at the Company's discretion.

07:40 EDT Nextech3D.ai announces new 3D modeling deals - Nextech3D.ai announced a number of new 3D modeling deals across a large variety of industries worldwide. The company said, "Sales continue to grow at an exponential rate, meaning that it's producing more 3D models each month with no end in sight, highlighting Nextech3D.ai as a major player in the rapidly growing $100 billion global 3D modeling market for eCommerce. The Company recently announced it has landed a major enterprise 3D model deal with an S&P 500 Company Top 10 Retailer. As mentioned in a previous release, in addition to being a preferred supplier to Amazon and signing large enterprise deals, Nextech3D.ai continues to see record demand for 3D models and anticipates Q1 2023 will exceed sales numbers from Q4 2022. This positions Nextech3D.ai as the leader for 3D modeling in the global $5.5 trillion eCommerce ecosystem."

07:38 EDT ARway signs multiple SDK deals for indoor positioning, AR navigation - ARway announced that the Company has signed five new deals for its Software Development Kit. MPSKIN - SDK Partner: Using the ARway platform for existing map management of virtual tours and implementing new augmented reality tours on site at museums & art Galleries; The TRIBE - SDK Partner: Using ARway to build a custom AR-powered app for their marketing agency to showcase capabilities to clients; Suggesto - SDK Partner: Using ARway for a new experiential location-based game for its local customers in Italy; ENCORE EAS: Entertainment Technology Provider based in MENA. Using ARway in Airports for Wayfinding and Guided tours; Rayqube - SDK Partner: Agency based in Dubai building an experiential AR app for some of their select client locations to drive social engagement/sharing. These SDK deals range in size from $600-$10,000 based on the usage of the platform, and are within various industries representing a wide range of use cases for ARway technology.

07:36 EDT Incannex announces results of interim review on Phase 2 program for GAD - Incannex Healthcare announces results of an interim review of the conduct, safety and data from its ongoing Phase 2 clinical trial assessing its proprietary psilocybin-assisted psychotherapy program for Generalised Anxiety Disorder, GAD, known as "PsiGAD". IHL has reviewed the interim data from the first 29 participants to complete the treatment protocol and completed a conditional power analysis using the interim data to model and project total study data. Given the strong results to date, the company found that there is a high probability that the total study will show a statistically significant benefit for the psilocybin treatment arm over the placebo treatment arm. A review was also conducted by an independent DSMB, which reviewed the available data from the first 37 out of 72 participants. The DSMB recommended no adjustments to the original study design or sample size. IHL announced the original study on December 8, 2020, under the heading: Incannex partners with Monash University to conduct a world-first clinical trial: Psilocybin-assisted psychotherapy in the treatment of Generalised Anxiety Disorder. The study design is based on the hypothesis that psilocybin-assisted psychotherapy will show a large treatment effect, as measured by a reduction in HAM-A scores compared to the control condition. The trial employs a team of experienced and qualified clinicians and researchers who undergo specialist training before they deliver and assess the treatment. To date, over 45 participants have been enrolled in the study, with 29 participants having now completed the treatment protocol and main outcome assessment following treatment. Treatment of all 72 trial participants is anticipated to be completed in the fourth quarter of 2023. CEO and Managing Director of Incannex, Joel Latham, said: "The results from the interim analysis of Incannex's Phase 2 clinical trial provide us with encouragement that our PsiGAD psilocybin-assisted psychotherapy treatment protocol has the potential to transform the lives of people suffering from anxiety, I believe IHL is leading the way in research on novel treatments for this debilitating indication. Even though the results must remain blinded until the conclusion of the trial, the confidential review has given us the confidence to commence manufacture of our own psilocybin drug product with the appointment of Catalent, progress planning of our pivotal trials and commence drafting our FDA IND application for the PsiGAD treatment program. The Clinical Psychedelic Lab at Monash University has overseen training of 14 psychotherapists to work on the phase 2 trial, demonstrating that this transformational treatment is scalable to many therapists and patients throughout the world."

07:35 EDT Oatly Group expects gross profit margin 35%-40% in longer-term - Longer-term, the Company expects: To generate gross profit margin in the range of 35% to 40%, Adjusted EBITDA margin in the mid- to high-teens.

07:33 EDT Oatly Group expects positive adjusted EBITDA for FY24 - The Company believes this progress will enable full year fiscal 2024 to deliver positive adjusted EBITDA.

07:26 EDT Oatly Group announces financing commitments of $425M - Oatly Group entered into privately negotiated agreements with certain investors pursuant to which Oatly agreed to sell and the investors agreed to purchase from Oatly $300M aggregate principal amount of 9.25% Convertible Senior PIK Notes due 2028. Oatly also announced today that, on March 15, 2023, it entered into a commitment letter to amend its Sustainable Revolving Credit Facility Agreement, and a commitment letter documenting a $125M term loan B credit facility commitment.

07:21 EDT Chembio Diagnostics board recommends stockholders tender shares - Chembio Diagnostics released a letter to stockholders concerning the pending tender offer by Biosynex SA, which read in part, " As previously disclosed, Chembio Diagnostics entered into an Agreement and Plan of Merger, dated as of January 31, 2023, with Biosynex SA, a French societe anonyme, and Project Merci Merger Sub, Inc., a Nevada corporation and wholly-owned indirect subsidiary of Biosynex. Pursuant to the Merger Agreement, the Purchaser commenced a tender offer to purchase all of the issued and outstanding shares of the Company's common stock, par value $0.01 per share, for a purchase price of $0.45 per share, net to the seller in cash, without interest and subject to any required tax withholding. The Offer was initially scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023. Today, Biosynex announced an extension of the Offer until 6:00 p.m., New York City time, on March 28, 2023. I believe Chembio is at a critical juncture and it is important to communicate the best available information to our stockholders at this time. The decision to enter into the Merger Agreement was arrived at following an extensive strategic review as detailed in the Schedule 14D-9 filed with the U.S. Securities and Exchange Commission on February 14, 2023. As further disclosed in the Schedule 14D-9, the Company faces ongoing operational and financial challenges if it stays an independent company as a result of not enough Shares being tendered in the Offer and the transactions contemplated by the Merger Agreement not being consummated. These challenges include: Credit Agreement; Debt Maturity and Covenants. Our Credit Agreement has a September 4, 2023 maturity date, and we do not currently believe that replacement debt or equity financing arrangements are or will be available to us or, if available to us, will be on acceptable terms. In addition, the Credit Agreement includes a minimum total revenue covenant, and based on our financial performance to date for the current quarter, we do not believe that we will be in compliance for the four fiscal quarters ended March 31, 2023. Our lender has previously informed us that it will not agree to any restructuring of the Credit Agreement, and as a result we may be forced to pursue a bankruptcy or restructuring proceeding when the debt matures or pursue a transaction or financing arrangement that could be dilutive to stockholders. Potential Nasdaq Delisting. We do not anticipate meeting the minimum bid price requirement for continued listing on the Nasdaq Capital Market, and there is a strong likelihood that Nasdaq will notify the Company on or shortly after April 3, 2023 that it will be subject to delisting. While the Company may appeal a Nasdaq delisting determination to a Nasdaq hearings panel, there can be no assurance that any such appeal would be successful, particularly since we initially received a deficiency letter on April 5, 2022 and have already received a 180-day extension to regain compliance. Further, even if the Company were in a position to pursue a reverse stock split or other similar corporate action in an effort to regain compliance with the minimum bid requirement, there can be no assurance that it would be able to obtain the requisite stockholder approval under Nevada law. If the Company's common stock were to be delisted, this would adversely affect the Company's ability to publicly or privately sell equity securities and negatively impact the liquidity of your common stock. Net Losses and Going Concern Doubts. The Company's net loss of approximately $33.9 million for the year ended December 31, 2021 and $22.4 million for the nine months ended September 30, 2022 coupled with ongoing liquidity concerns have resulted in the Company's conclusion that there is substantial doubt about its ability to continue as a going concern. As further described in the Schedule 14D-9, our Board of Directors unanimously determined that the Merger Agreement and the transactions contemplated by the Merger Agreement are in the best interests of stockholders and recommended that stockholders tender their shares in the Offer. As part of reaching this determination and recommendation, the Board considered the premium the offer price represented, the certainty the tender offer and merger would provide stockholders, and the business reputation, management and financial resources of Biosynex."

07:18 EDT Biosynex extends tender offer for shares of Chembio Diagnostics - Biosynex announced that Project Merci Merger Sub has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of Chembio Diagnostics, at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on March 28, 2023, unless further extended. The tender offer was previously scheduled to expire at one minute after 11:59 p.m., New York City time, on March 14, 2023. All other terms and conditions of the tender offer remain unchanged. Securities Transfer Corporation, the depositary and paying agent for the tender offer, has indicated that, as of 11:59 p.m., New York City time, on March 14, 2023, approximately 12,664,710 Shares had been validly tendered into and not validly withdrawn from the tender offer, representing approximately 34.5% of the Shares then outstanding. Stockholders who have already tendered their Shares into the tender offer do not have to re-tender their Shares or take any other action as a result of the extension of the expiration time of the tender offer.

07:16 EDT Genius Group redeemable discount coupons available for all shareholders - Genius Group announced their redeemable discount coupons are now available for shareholders of the record date February 28, 2023 to claim on Upstream's trading app. Upon a successful claim, shareholders may redeem the NFT for iGEMs on Genius Group's Edtech platform, GeniusU equivalent to $10 per share. Shareholders of the record date February 28, 2023 will be able to redeem the coupon NFT and iGEMs for discounts in courses or products. For non-objecting shareholders of record that currently maintain positions in brokerage accounts, their ownership will be verified via Genius's shareholder list. Shareholders that are objecting may receive a request from Upstream via email to provide a copy of their brokerage account statement for the record date of February 28, 2023, that shows a long position of Genius Group.

07:15 EDT Microvast selected by MAFI & TREPEL as battery supplier for EV tractors - Microvast Holdings has announced a partnership to supply lithium-ion batteries for MAFI Transport-Systeme GmbH and TREPEL Airport Equipment GmbH. "We're creating the next generation of batteries and shaping new opportunities for a more sustainable future" Microvast's MV-C Gen 4 high-energy lithium-ion battery packs have been specifically designed for commercial vehicle applications, offering a high energy density of 53.5Ah, a long cycle life of 5,000+ cycles, and a modular pack design for easy installation. "MAFI & TREPEL conducted thorough research and chose Microvast as their trusted partner due to Microvast's extensive experience in supplying advanced battery solutions for high-power commercial vehicles," explained Sven Woyciniuk, Head of Electrical Engineering at MAFI & TREPEL. "Microvast's high-performance battery technologies provide the required high energy density, enabling us to deliver the high power and performance our industrial vehicles require to move heavy loads and perform demanding industrial applications," continued Woyciniuk.

07:13 EDT Pure Sunfarms' Soar brand expands limited batch collection - Pure Sunfarms Corp introduces a new 1g pre-roll offering through Soar. Finished with a Dutch crown for an even burn, each 1g pre-roll features cultivars thoughtfully selected for their unique and exotic genetics. Soar's 1g pre-rolls are offered in the following genetics: Pineapple God Pre-Roll 1g: This 1g pre-roll features Pineapple God, a potent and aromatic cross of God Bud and Black Cherry Punch. From stacked colas of sticky green, pink and purple buds, this indica offers exotic aromas of tropical fruit. Cherry Do-Si-Dos Pre-Roll 1g: This 1g pre-roll features Cherry Do-Si-Dos, a dank and aromatic cross of Black Cherry Punch and Do-Si-Dos. From dense, dark and trichome-abundant buds, this indica offers strong sour fruit and earthy flavours balanced with floral and funky notes. Alien Fuel Pre-Roll 1g: This 1g pre-roll features Alien Fuel, an exclusive hybrid of Jet Fuel Gelato and MAC 1. From attractive pale green and purple buds, it offers a balance of citrus and herbal aromas. Soar's 1g pre-rolls are now available in BC and Alberta and will be in Ontario in the months ahead. Strain selection will vary by province.

07:11 EDT Chart Industries, ZEV Stations execute MoU for hydrogen equipment - Chart Industries and ZEV Stations executed a Memorandum of Understanding, MoU, enabling the two companies to collaborate on novel deployment for US-based, multimodal hydrogen stations with Chart equipment. Working together, the companies' goal is development of fast-fuel multiple modes for heavy-duty transportation at the same station, uniting different standards of gaseous and liquid hydrogen vehicle fueling using high flow and efficiency liquid pumping. Under this agreement, Chart will supply liquid hydrogen fuel station equipment and hydrogen liquefaction, to support ZEV Station's multimodal hydrogen stations. This type of station will service hydrogen vehicles up to Class 8 heavy-duty trucks using Chart's liquid-based equipment enabling at least 8 kg per minute fills. "ZEV Station has an innovative approach to scaling heavy-duty highway stations for higher vehicle throughput than today's stations," stated Jill Evanko, Chart's CEO and President. "This MoU brings Chart's extensive technology and equipment to the project. We look forward to supporting ZEV Station's endeavors to deliver the fastest fueling options to the hydrogen vehicle market."

07:09 EDT Moving iMage: No direct financial exposure to Silicon Valley or Signature Bank - Moving iMage Technologies said it has no direct financial exposure to Silicon Valley Bank or Signature Bank in the wake of the banks being closed by regulators. MiT utilizes banking services from Bank of the West, a subsidiary of BMO Financial Group, a highly diversified financial services provider and the 8th largest bank, by assets, in North America. Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation on March 10 . The CDFPI has appointed the Federal Deposit Insurance Corporation as receiver of SVB. Signature Bank, New York, NY, was closed on March 12, 2023 by the New York State Department of Financial Services, which appointed the Federal Deposit Insurance Corporation as receiver.

07:06 EDT Aravive expects cash to sustain operations into Q4 - As of December 31, 2022, cash and cash equivalents were approximately $53.7 million, compared to approximately $27.9 million as of September 30, 2022. During October 2022, the Company received a $6 million milestone payment from the Company's licensee, 3D Medicines, Inc. and raised approximately $40 million in net proceeds from a private placement offering. The Company believes that its existing cash and cash equivalents will be sufficient to sustain operations into the fourth quarter of 2023.

07:04 EDT FiscalNote announces Fireside State selected by Georgia Legislature - FiscalNote announced that Fireside State, the all-in-one constituent relationship management SaaS platform specifically designed for lawmakers and staff at state and local levels of government, has been selected by the Georgia Legislature the Office of the Lieutenant Governor, and members of the DeKalb County Board of Commissioners to serve as their central hub for communications and relationship management needs with Georgia citizens.

07:03 EDT Ideanomics unit enters partnerships with Phenix Air Corp, Pure Flight - Ideanomics announced that its subsidiary Energica Motor Company, maker of the world's best high-performance electric motorcycle, has entered into two separate partnerships with the French tech consulting firm Phenix Air Corp and Pure Flight to develop all-electric solutions for ultra-light and light aircraft. The collaboration is being executed by Energica's Energica Inside business unit. As part of the collaboration with Phenix Air Corp, Energica's electric powertrain has been integrated into an airplane propeller to assess performance and conduct testing. The powertrain will then be integrated into an ultralight seaplane to test in-flight performance. In California, a parallel project is underway with Phenix Air Corp to integrate Energica's powertrain into a purpose-built Sonex airframe for small aircraft applications. The project will test the performance and range of the EV conversion for multiple use cases, including training courses, cruise intrastate travel and aerobatics.

06:51 EDT Eton Pharma acquires rare disease product candidate ET-600 - Eton Pharmaceuticals announced the acquisition of rare disease product candidate ET-600 from Tulex Pharmaceuticals. ET-600 is an innovative product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the U.S. Eton expects to submit a New Drug Application, or NDA, for the product to the FDA in the Q2 of 2024, which could allow for an approval and launch of the product in early 2025. If approved, ET-600 is expected to be a patent-protected, durable product that can generate significant long-term revenue and profit for the company.

06:35 EDT Arthur J. Gallagher acquires AT Squared, terms undisclosed - Arthur J. Gallagher announced the acquisition of UK-based AT Squared. Terms of the transaction were not disclosed. FE Protect is an insurance broker specializing in the UK education sector. Based in Merseyside, England, it has a particular focus on further education, which includes post-secondary learning distinct from higher education, in addition to serving independent schools and universities. FE Protect also operates under the brands Education Protect and Education Protect Scotland. Andrew Thomson, Alan Tune and their team will operate as part of Gallagher's public sector and education practice under the direction of Tim Devine, Regional Managing Director.

06:34 EDT Credit Suisse falls 20% after top holder says not investing more - Shares of Credit Suisse are moving lower after its top shareholder ruled out investing any more money in the bank. "The answer is absolutely not, for many reasons outside the simplest reason, which is regulatory and statutory," Saudi National Bank Chairman Ammar Al Khudairy said in an interview on Bloomberg TV. Shares of Credit Suisse are down 21% to $1.99 in premarket trading.

06:02 EDT Alcoa to reduce production 75% at Portland Aluminium smelter in Australia - Alcoa Corporation announced that the Portland Aluminium smelter in the state of Victoria in Australia will begin to immediately reduce its overall production due to operational instability. Production at the smelter will be reduced to approximately 75% of the site's total consolidated capacity of 358,000 metric tons per year, or mtpy. Alcoa's share of the total capacity is 197,000 mtpy. The smelter, which has a total of 408 pots, had previously been operating at about 95% of its total capacity. The smelter has recently faced instability and challenges related to the production of rodded anodes, which are necessary to convey electricity into the smelting pots.

05:22 EDT Just Eat Takeaway.com files for deregistration from SEC in U.S. - Just Eat Takeaway.com N.V. announced Monday that it will file for deregistration of its securities under the Securities and Exchange Act of 1934. Deregistration of its securities from the SEC will reduce reporting costs and complexity, the company said in a statement. Deregistration is expected to become effective 90 days after the filing of the Form 15F. "The company's main considerations for the deregistration are the low trading volumes of the company's securities in the United States. In addition, the costs and expenses associated with being registered under the Exchange Act, the auditing, legal and other costs associated with continuing to make SEC filings, and the burdens placed on company management to comply with the continued reporting requirements in the United States are significant and are not considered to be offset by the benefits from having its securities registered under the Exchange Act." Reference Link

05:08 EDT Celyad to recognize non-cash impairment of EUR 35.1M for FY22 - Celyad announced a non-cash impairment of its goodwill and intangible oncology assets.This impairment comes as a result of the company's strategic shift in focus away from clinical development and the early stage nature of the implementation of the Celyad 2.0 strategy: shifting from an organization focused on clinical development to one prioritizing R&D discovery and the monetization of its intellectual property, or IP, portfolio through partnerships, collaborations and license agreements. As, to date, no effective sublicense contract nor collaboration contract was concluded, some uncertainty exists on the timing and amount of the deal flow and associated short, medium and long term revenues. Given this uncertainty, and per accounting standards, the company will recognize a full impairment loss on the remaining value of goodwill, In Process Research and Development, and Horizon Discovery's shRNA platform, resulting in a non-cash impairment of EUR 20.5M on a statutory basis and EUR 35.1M on a consolidated basis for the financial year ended December 31, 2022. The net assets of the company as of December 31, 2022, on a BE-GAAP non-consolidated basis, have fallen below half of the company's capital. As a result, in accordance with Article 7:228 of the Belgian Code for Companies and Associations, the board of directors plans to submit for a vote, at its May 5 shareholders' meeting, its business plan including a proposal to continue the company's activities. The board of directors will publish a detailed report regarding this proposal on or around April 3, together with the convocation with proposed resolutions for the shareholders' meeting. The audit for fiscal year 2022 has not yet been fully completed.

05:01 EDT Mainz Biomed enters partnership with Labor Staber in Germany - Mainz Biomed announced a partnership with Dr Staber & Kollegen, or Labor Staber, as part of its growing network of laboratories offering ColoAlert, its product that is a at-home screening test for colorectal cancer. For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.

04:55 EST Insulet to replace SVB Financial in S&P 500 at open on 3/15 - The FDIC announced that it has taken SVB Financial Group into FDIC Receivership and therefore SVB Financial Group is no longer eligible for inclusion.